Genetic effects of methyl benzimidazole-2-yl-carbamate on Saccharomyces cerevisiae.
The genetic effects of the mitotic inhibitor methyl benzimidazole-2-yl-carbamate (MBC) have been studied in Saccharomyces cerevisiae. MBC had little or no effect on the frequency of mutation. In some experiments MBC caused an increase in the frequency of mitotic recombination; however, this effect was small and not reproducible. The primary genetic effect of MBC was to induce mitotic chromosome loss at a high frequency. Chromosome loss occurred at equal frequencies for all chromosomes tested (13 of 16). Cells which had lost multiple chromosomes were found more frequently than predicted if individual chromosome loss events were independent. The probability of loss for a particular chromosome increased with length of time cells were incubated with MBC. MBC treatment also increased the frequency at which polyploid cells were found. These results suggested that MBC acted to disrupt the structure or function of the mitotic spindle and cause chromosome nondisjunction.
D000470:Alkaloids / Q000494:pharmacology; D001562:Benzimidazoles / Q000494:pharmacology*; D002219:Carbamates; D002869:Chromosome Aberrations; D002875:Chromosomes / Q000187:drug effects; D003208:Concanavalin A / Q000494:pharmacology; D003513:Cycloheximide / Q000494:pharmacology; D004352:Drug Resistance, Microbial; D008040:Genetic Linkage; D008938:Mitosis / Q000187:drug effects*; D011995:Recombination, Genetic / Q000187:drug effects; D012441:Saccharomyces cerevisiae / Q000187:drug effects* / Q000235:genetics
D000470:Alkaloids; D001562:Benzimidazoles; D002219:Carbamates; D003208:Concanavalin A; C007160:cryptopleurine; D003513:Cycloheximide; C006698:carbendazim